A Randomized, Phase II Study of Two Dose Levels of ATN-224 in Patients With Biochemically Relapsed, Early Stage Prostate Cancer Not on Hormone Therapy

Trial Profile

A Randomized, Phase II Study of Two Dose Levels of ATN-224 in Patients With Biochemically Relapsed, Early Stage Prostate Cancer Not on Hormone Therapy

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 31 May 2009

At a glance

  • Drugs Bis-choline tetrathiomolybdate (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Sponsors Attenuon
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 31 May 2009 Interim results presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO-2009).
    • 28 May 2009 Planned number of patients changed from 50 to 50.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top